Geode Capital Management LLC Purchases 21,396 Shares of Immunome, Inc. (NASDAQ:IMNM)

Geode Capital Management LLC grew its position in Immunome, Inc. (NASDAQ:IMNM) by 1.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,228,851 shares of the company’s stock after buying an additional 21,396 shares during the period. Geode Capital Management LLC’s holdings in Immunome were worth $13,054,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Immunome by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after purchasing an additional 4,874 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after buying an additional 624,045 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Immunome in the fourth quarter valued at approximately $75,000. Virtu Financial LLC acquired a new stake in shares of Immunome in the fourth quarter valued at approximately $486,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Immunome during the 4th quarter worth approximately $124,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Guggenheim dropped their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Lake Street Capital started coverage on shares of Immunome in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price objective on the stock. Lifesci Capital started coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens restated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.14.

Immunome Stock Performance

Shares of Immunome stock opened at $8.00 on Tuesday. Immunome, Inc. has a 52-week low of $5.15 and a 52-week high of $16.81. The stock has a market cap of $695.61 million, a PE ratio of -0.99 and a beta of 2.05. The firm has a 50-day moving average of $8.15 and a 200-day moving average of $10.32.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Equities research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Activity at Immunome

In related news, CEO Clay B. Siegall acquired 150,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 7,000 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $8.21 per share, with a total value of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares in the company, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 306,400 shares of company stock worth $2,322,995. Company insiders own 8.60% of the company’s stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.